Current Standard of Care for Patients with Multiple Myeloma Based on Their Eligibility for Autologous Stem-Cell Transplant

Video Library —April 23, 2020
Charise Gleason, MSN, NP-BC, AOCNP
Kathryn Maples, PharmD, BCOP
Chelsea Sprouse, RN-BSN, MSN, NP-C

Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, RN-BSN, MSN, NP-C, discuss the current standard of care for both high- and low-risk patients with newly diagnosed or recurrent/refractory multiple myeloma who are initially not eligible for autologous stem-cell transplant and who subsequently become transplant-eligible.

Related Articles
Dealing with Multidrug Combination Therapy for Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.
Best Practices in Counseling Multiple Myeloma Patients on Therapeutic Options
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.
Landscape Shifts in Treating Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Last modified: May 22, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code